['NASDAQ:AZN opened at $62.38 on Friday. The company has a market cap of $193.27 billion, a price-to-earnings ratio of 27.40, a price-to-earnings-growth ratio of 1.32 and a beta of 0.50. The company has a current ratio of 1.23, a quick ratio of 1.01 and a debt-to-equity ratio of 1.54. AstraZeneca PLC has a twelve month low of $46.48 and a twelve month high of $62.86. The stock has a fifty day simple moving average of $59.26 and a 200-day simple moving average of $57.55. ', '\n\n\n\n\n\n                 AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Wednesday, July 28th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. AstraZeneca had a return on equity of 40.02% and a net margin of 12.77%. The firm had revenue of $8.22 billion for the quarter, compared to analyst estimates of $7.79 billion.  As a group, equities research analysts predict that  AstraZeneca PLC will post 2.65 EPS for the current fiscal year. ', 'A number of brokerages have issued reports on AZN. UBS Group  reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 19th. Deutsche Bank Aktiengesellschaft  reaffirmed a “buy” rating on shares of AstraZeneca in a report on Monday, October 11th. Morgan Stanley  reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Friday, September 17th. JPMorgan Chase & Co. assumed coverage on AstraZeneca in a research report on Thursday, August 12th. They set an “overweight” rating for the company. Finally, Citigroup  reiterated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, July 21st. One investment analyst  has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company  has a consensus rating of “Buy” and a consensus price target of $124.00.', 'About AstraZeneca', 'AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.', 'Read More: How is Preferred Stock Different from Common Stock?', 'Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).', '', '', "Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.", '767,922 Shares in Snap Inc. (NYSE:SNAP) Bought by Amundi']


